Ambry Genetics and Tempus Collaborate on Germline and Somatic Testing Services
Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext and CancerNext-Expanded assays.
Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext and CancerNext-Expanded assays.
Myriad Genetics will acquire Intermountain Precision Genomics' Precise Tumor Test, the Precise Liquid Test, and a CLIA-certified laboratory.
Illumina will divest GRAIL after a federal appeals court upheld an FTC ruling that it should unwind its deal with GRAIL.
Philips and NYU Langone Health has announced an 8-year strategic partnership aimed at enhancing patient care through further innovation.
Read MoreBD has announced that Ronald Silverman, MD, FACS, has been named executive VP and chief medical officer of BD, effective Dec. 4, 2023.
Read MorePrinciple Health Systems has announced the strategic acquisition of BioStat Laboratory, a Dallas-based laboratory.
Read MoreLabcorp announced the completion of a laboratory agreement with Legacy Health to acquire select assets of Legacy’s outreach lab business.
Read MoreThe grant will be used for the development and validation of a custom protein biomarker panel to measure Parkinson’s disease activity.
Read MoreGeneoscopy’s multi-target stool RNA (mt-sRNA) biomarker panel is designed to detect precancerous lesions and colorectal cancer.
Read MoreVeracyte and Illumina will develop high-performing molecular tests as decentralized IVD tests on Illumina’s NextSeq 550Dx NGS instrument.
Read MoreFabric Genomics is collaborating with DNAnexus to empower clinical labs to rapidly access and analyze large-scale clinical whole genome data.
Read MoreDiadem formed a strategic collaboration with Quest Diagnostics to improve access to blood tests for evaluating the risk of Alzheimer’s.
Read MoreVersant’s plans include entering into agreements with independent pathology practices to spur more interest in digital pathology.
Read MoreQIAGEN and Myriad Genetics announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer.
Read MoreThe Association for Molecular Pathology announced the appointment of its next CEO, who will be instated effective Jan. 3, 2024.
Read MoreEvidation has been awarded a contract by BARDA to fund the 2023 Influenza-like Illness (ILI) Detect & Protect Studies.
Read MoreRevvity announced a distribution agreement with SCIEX aimed at advancing mass spectrometry solutions in newborn screening products.
Read MoreTeselaGen Biotechnology, a software company providing an all-in-one platform for scalable biotech...
Read More